Equity Overview
Price & Market Data
Price: $0.26
Daily Change: $0.00 / 0.00%
Daily Range: $0.26 - $0.285
Market Cap: $2,104,939
Daily Volume: 23,164
Performance Metrics
1 Week: 4.00%
1 Month: 52.94%
3 Months: 76.39%
6 Months: 76.87%
1 Year: -78.86%
YTD: 94.47%
Company Details
Employees: 7
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
ZyVersa Therapeutics, Inc. operates as a clinical stage biopharmaceutical company that develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial for the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity. The company has a license agreement with L&F Research LLC, and InflamaCORE, LLC. ZyVersa Therapeutics, Inc. was founded in 2014 and is based in Weston, Florida.